AVITA Medical Announces Positive Interim Results for Cohealyx® Wound Treatment

Study shows significant reduction in time to skin grafting for full-thickness wounds

Apr. 14, 2026 at 1:25pm

Got story updates? Submit your updates here. ›

A translucent X-ray photograph showing the intricate internal structures of a human skin graft, with a network of glowing blood vessels and tissue against a dark background, conceptually representing the accelerated wound healing enabled by the Cohealyx product.Cohealyx's ability to accelerate vascularization and wound bed preparation could lead to faster skin grafting and improved patient outcomes.New Orleans Today

AVITA Medical, a leading therapeutic acute wound care company, announced positive interim results from its Cohealyx-I multi-center study. The study demonstrated a reduction of nearly 20 days in mean time to skin grafting (13.6 days vs 33.2 days benchmark) for patients with full-thickness wounds. The interim analysis of 40 patients showed a median time to grafting of 11 days, with grafting achieved as early as 5 days.

Why it matters

Preparing the wound bed efficiently remains a key challenge in managing full-thickness wounds. These interim results show that Cohealyx supports vascularization and enables earlier grafting, which is central to improving patient outcomes. The meaningful reduction in time to grafting and high investigator satisfaction highlight Cohealyx's potential as a differentiated solution to drive broader adoption and improve wound healing.

The details

The interim analysis demonstrated statistical superiority (p<0.001) versus a literature-derived benchmark, based on the lower bound of the 95% confidence interval (28 days). The benchmark was derived from a meta-analysis of published data on leading dermal matrices, representing approximately 900 patients. Investigators reported 90% satisfaction at the time of grafting, including among predominantly first-time users, supporting consistent performance and potential for broader adoption in clinical practice.

  • The interim data will be presented at an AVITA Medical symposium on April 15, 2026.
  • AVITA Medical will host a KOL webinar to review the data and case studies on April 16, 2026 at 4:30 p.m. ET.

The players

Derek Bell, MD

Professor of Plastic Surgery and Kessler Burn Director, University of Rochester Medical Center

Jonathan E. Schoen, MD, MPH, FACS, FABA

Medical Director, UMCNO Verified Burn Center, and Associate Professor of Clinical Surgery, Section of Burns/Trauma/Critical Care Surgery, LSUHSC School of Medicine at New Orleans

Cary Vance

Interim Chief Executive Officer of AVITA Medical

Lourdes Castañón, MD, FACS

University of Arizona

Got photos? Submit your photos here. ›

What they’re saying

“Preparing the wound bed efficiently remains one of the key challenges in managing full-thickness wounds. These interim results show that Cohealyx supports vascularization and enables earlier grafting, which is central to improving patient outcomes.”

— Derek Bell, MD, Professor of Plastic Surgery and Kessler Burn Director, University of Rochester Medical Center

“This data strengthens our belief that Cohealyx can set a new benchmark in wound bed preparation. The meaningful reduction in time to grafting and high investigator satisfaction highlight its potential as a differentiated solution with the ability to drive broader adoption as we work to improve each stage of the wound healing pathway.”

— Cary Vance, Interim Chief Executive Officer of AVITA Medical

What’s next

The full dataset from the Cohealyx-I study is expected in 2026.

The takeaway

These positive interim results for AVITA Medical's Cohealyx product demonstrate its potential to significantly accelerate wound healing by reducing the time required for skin grafting. This could lead to improved patient outcomes and broader adoption of the technology in clinical practice.